- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Hematology
Volume 2012 (2012), Article ID 984986, 3 pages
Rituximab-Induced Coronary Vasospasm
1Department of Oncology, Niagara Health System, St. Catharines, ON, Canada L2R 2Z7
2Department of Medical Oncology & Hematology, Princess Margaret Hospital, Room 5-227, 610 University Avenue, Toronto, ON, Canada M5G 2M9
Received 1 March 2012; Accepted 12 April 2012
Academic Editors: M.-C. Kyrtsonis and P. Tsirigotis
Copyright © 2012 Linda Lee and Vishal Kukreti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. Seruga, L. Sterling, L. Wang, and I. F. Tannock, “Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials,” Journal of Clinical Oncology, vol. 29, no. 2, pp. 174–185, 2011.
- J. D. Hainsworth, S. Litchy, H. A. Burris et al., “Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 20, pp. 4261–4267, 2002.
- M. Herold, A. Haas, S. Srock et al., “Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German study group hematology and oncology study,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1986–1992, 2007.
- W. Hiddemann, M. Kneba, M. Dreyling et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group,” Blood, vol. 106, no. 12, pp. 3725–3732, 2005.
- R. Marcus, K. Imrie, P. Solal-Celigny et al., “Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4579–4586, 2008.
- J. C. Byrd, J. K. Waselenko, T. J. Maneatis et al., “Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance,” Journal of Clinical Oncology, vol. 17, no. 3, pp. 791–795, 1999.
- L. E. Van Der Kolk, A. J. Grillo-López, J. W. Baars, C. E. Hack, and M. H. J. Van Oers, “Complement activation plays a key role in the side-effects of rituximab treatment,” British Journal of Haematology, vol. 115, no. 4, pp. 807–811, 2001.
- U. Winkler, M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert, “Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8),” Blood, vol. 94, no. 7, pp. 2217–2224, 1999.
- D. G. Maloney, A. J. Grillo-López, D. J. Bodkin et al., “Idec-c2b8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 15, no. 10, pp. 3266–3274, 1997.
- M. Siano, E. Lerch, L. Negretti et al., “A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function,” Clinical Cancer Research, vol. 14, no. 23, pp. 7935–7939, 2008.
- J. D. Armitage, C. Montero, A. Benner, J. O. Armitage, and G. Bociek, “Acute coronary syndromes complicating the first infusion of rituximab,” Clinical Lymphoma and Myeloma, vol. 8, no. 4, pp. 253–255, 2008.
- V. Garypidou, V. Perifanis, K. Tziomalos, and S. Theodoridou, “Cardiac toxicity during rituximab administration,” Leukemia and Lymphoma, vol. 45, no. 1, pp. 203–204, 2004.
- M. De Forni, M. C. Malet-Martino, P. Jaillais et al., “Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study,” Journal of Clinical Oncology, vol. 10, no. 11, pp. 1795–1801, 1992.
- R. G. Dent and I. McColl, “Letter: 5-fluorouracil and angina,” Lancet, vol. 1, no. 7902, pp. 347–348, 1975.
- S. Rezkalla, R. A. Kloner, J. Ensley et al., “Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study,” Journal of Clinical Oncology, vol. 7, no. 4, pp. 509–514, 1989.
- G. Cianci, M. F. Morelli, K. Cannita et al., “Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity,” British Journal of Cancer, vol. 88, no. 10, pp. 1507–1509, 2003.